KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA’s expertise in delivering global biopharma licensing deals and in the ophtalmology space
